{"id":11,"date":"2024-02-05T07:24:17","date_gmt":"2024-02-05T07:24:17","guid":{"rendered":"https:\/\/atxpsychedelictherapy.com\/?page_id=11"},"modified":"2024-02-05T07:24:17","modified_gmt":"2024-02-05T07:24:17","slug":"psychedelic-research","status":"publish","type":"page","link":"https:\/\/atxpsychedelictherapy.com\/?page_id=11","title":{"rendered":"Psychedelic Research"},"content":{"rendered":"\n
\n
\n
\n

Ketamine Research \u2014 Overview<\/p>\n<\/div>\n\n\n\n

\n

Since 2010, doctors have been prescribing ketamine in low doses to people with treatment resistant depression, but it may only be administered in the presence of a licensed physician.<\/p>\n\n\n\n

The most recent research is showing that intravenous or intramuscular administration provides the best outcome, when using ketamine in psychedelic assisted therapy. The way ketamine works is similar to what we\u2019ve learned about MDMA and psilocybin; Ketamine administration rapidly \u2026 increases the number, complexity, and strength of connections between neurons, and this effect appears to be directly correlated with its antidepressant benefit,\u201d said Dr. Kelley O\u2019Donnell, a psychiatrist who studies and provides psychedelic-assisted psychotherapy at New York University\u2019s Langone Center for Psychedelic Medicine.<\/p>\n\n\n\n

The belief is that ketamine, similar to studies on psilocybin, helps generate new connections between neurons that have been lost over time as a result of depression. We do know that ketamine causes a boost in the neurotransmitter, glutamate. Glutamate is known to stimulate new communication between brain cells that might have been damaged by stress and depression.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\"ketamine
https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9207256\/<\/figcaption><\/figure>\n<\/div>\n\n\n\n
\n
\n
\n

Research on<\/strong> Psychedelic Assisted Therapy<\/strong><\/p>\n<\/div>\n\n\n\n

\n

Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9207256\/<\/a><\/p>\n\n\n\n

The New Yorker: Ketamine therapy is going mainstream. Are we ready? https:\/\/www.newyorker.com\/culture\/annals-of-inquiry\/ketamine-therapy-is-going-mainstream-are-we-ready<\/a><\/p>\n\n\n\n

The New York Times Podcast: \u201cThe Veterans Fighting to Legalize Psychedelics\u201d https:\/\/www.nytimes.com\/2023\/02\/22\/podcasts\/the-daily\/veterans-psychedelics-legalization.html<\/a><\/p>\n\n\n\n

The Harvard Gazette: \u201cKetamine found effective in treating severe depression\u201d https:\/\/news.harvard.edu\/gazette\/story\/2023\/05\/ketamine-found-effective-in-treatment-resistant-depression\/<\/a><\/p>\n\n\n\n

Johns Hopkins Psychedelic Research https:\/\/www.hopkinsmedicine.org\/psychiatry\/research\/psychedelics-research<\/a><\/p>\n\n\n\n

Michael Pollan \u201cHow to Change Your Mind\u201d ( book and Netflix Series) https:\/\/michaelpollan.com\/books\/how-to-change-your-mind\/<\/a><\/p>\n\n\n\n

\n